Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
CAS Registry Number
90028-76-5
Molecular formula
Not available
Molecular weight
Not available
Drug class
Botanical extractflavonoid and terpene-lactone phytopharmaceutical
Mechanism of action
Standardised Ginkgo biloba leaf extracts contain flavonoid glycosides and terpene lactones, including ginkgolides and bilobalide. Proposed activities include antioxidant effects, modulation of platelet-activating factor, microcirculatory effects and neuroprotective signalling. Composition and pharmacology are extract-specific.
Indications / reported uses
Certain standardised Ginkgo biloba extracts are authorised or licensed in some countries for symptomatic treatment of mild cognitive impairment or age-related cognitive symptoms, and/or support of peripheral circulation. Uses cannot be generalised to all Ginkgo preparations or dietary supplements.
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Ginkgo Biloba PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Ginkgo Biloba Permitted Daily Exposure (PDE) report (the Ginkgo Biloba PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Ginkgo Biloba Occupational Exposure Limit (OEL) report (the Ginkgo Biloba OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.